Lung cancer is the leading cancer killer among people living with HIV. As antiretroviral therapy (ART) has extended survival for HIV-infected individuals, non-AIDS-defining malignancies have become increasingly prominent. Lung cancer now represents 25-40% of non-AIDS-defining malignancies in HIV-infected individuals, making it the predominant cause of cancer-related mortality in this population.
PD-1/PD-L1 blockade has transformed NSCLC treatment. Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have become the cornerstone of modern immunotherapy for advanced non-small cell lung cancer. Nearly all advanced NSCLC patients without targetable oncogenic driver mutations now receive PD-1/PD-L1-based therapy as part of their standard treatment regimen, including in first-line and perioperative settings.
HIV-positive patients are routinely excluded from immunotherapy trials. Clinical trials for PD-1/PD-L1 inhibitors have historically excluded HIV-positive patients due to four principal concerns: risk of triggering immune reconstitution inflammatory syndrome (IRIS), amplified immune-related adverse events (irAEs) from pre-existing immune dysregulation, uncertain effects on HIV viral load and CD4+ T cell counts, and ethics committee obligations to protect vulnerable populations from potentially fatal risks.
A unique dual mechanism creates therapeutic opportunity. Emerging research suggests PD-1/PD-L1 blockade may have a dual immunomodulatory role in HIV-positive lung cancer patients: it can simultaneously enhance anti-tumor T-cell activity and potentially reverse HIV latency by rescuing exhausted HIV-specific T cells from PD-1-mediated functional suppression. This dual benefit positions checkpoint inhibitors as uniquely interesting drugs for this patient population.
PD-1 drives T cell exhaustion in chronic HIV infection. In HIV-infected individuals, chronic antigen exposure leads to sustained PD-1 upregulation on HIV-specific CD8+ T cells, impairing their antiviral activity. PD-1 also suppresses HIV transcription in CD4+ T cells and blocks TCR-mediated viral reactivation in latently infected cells, actively promoting viral persistence even in patients on ART.
PD-1+ cells constitute a key HIV reservoir. Flow cytometry studies reveal that PD-1-positive T cells harbor elevated levels of viral particles and represent a key viral reservoir in HIV-infected individuals. These cells maintain latent infection with integrated viral genomes that evade immune detection and remain refractory to ART, constituting the primary barrier to HIV cure. Regulatory T cells (Tregs), which are also enriched in PD-1 expression, further contribute to viral persistence.
PD-1 blockade reverses HIV latency and restores immune function. Blocking the PD-1/PD-L1 pathway reverses the latent infection status of CD4+ T cells in HIV infection. Studies show PD-1 blockade can reduce viral reservoir burden and, when combined with other therapies, offers potential toward ART-free virological control. Clinical monitoring of three lung cancer patients showed significant elevations in IL-6, HIV DNA, and cell-associated HIV RNA within 24 hours of PD-1 inhibitor infusion, suggesting transient reactivation followed by potential reservoir reduction.
The shock and kill approach may synergize with checkpoint blockade. The shock and kill strategy uses latency-reversing agents (including histone deacetylase inhibitors) to reactivate HIV in latently infected cells, exposing them to immune recognition. Emerging evidence suggests these agents significantly downregulate PD-L1 expression on cancer cells, synergizing with ICIs to enhance antitumor immunity by facilitating activated T cell infiltration into the tumor microenvironment, offering a potential ART-free HIV control strategy.
PD-1 inhibitors achieve meaningful response rates in HIV-positive NSCLC. Multiple retrospective studies demonstrate that PD-1 inhibitors such as nivolumab achieve objective response rates of 18-40% in HIV-positive NSCLC patients, with a median overall survival of 10.7 months, outcomes comparable to those observed in HIV-negative populations. A Phase II trial (IFCT-1602 CHIVA2) reported a 62.5% disease control rate with nivolumab after eight weeks, independent of baseline CD4+ T cell counts.
One patient showed dramatic HIV reservoir reduction. In a notable case reported by Guihot et al., one HIV-positive patient treated with nivolumab for lung cancer showed a marked decline in the HIV viral reservoir following treatment, suggesting a potential synergistic anti-HIV effect from checkpoint blockade combined with ART. This clinical observation directly supported the mechanistic hypothesis that PD-1 blockade reverses HIV latency in vivo.
Outcomes vary considerably but complete remissions are documented. Among case reports and small series, complete remissions have been documented in HIV-positive patients with lung squamous cell carcinoma treated with nivolumab. One patient maintained stable CD4+ T cell counts and undetectable viral load throughout treatment while achieving complete remission. However, a first-line study (n=5) reported a median OS of only 9.8 months with three patients experiencing rapid disease progression, highlighting outcome variability.
A 2023 multicenter study found no significant efficacy or safety differences. A large retrospective study by El Zarif et al. comparing HIV-positive (n=61) and HIV-negative (n=110) advanced NSCLC patients treated with PD-1/PD-L1 inhibitors found no significant differences in safety and efficacy between the two groups. Additionally, HIV-positive NSCLC tissues showed greater immune cell infiltration and elevated PD-L1 expression compared to HIV-negative cases.
Most studies report acceptable tolerability in ART-controlled patients. A 2018 study of seven HIV-positive lung cancer patients receiving PD-1 inhibitors demonstrated favorable overall tolerance with no grade 3-4 immune-related adverse events or treatment-related deaths. A 2019 JAMA-published trial of 30 pembrolizumab-treated HIV-positive patients with well-controlled HIV reported acceptable safety outcomes. A 2021 nivolumab safety study reported mild-to-moderate adverse events in 75% of participants but no opportunistic infections.
CD4+ T cell count thresholds may not predict irAE risk. The 2023 multicenter CATCH-IT consortium study showed that HIV-positive patients with CD4+ T cell counts below 200 cells/mL had comparable immune-related adverse event rates to those with counts above 200 cells/mL. A separate analysis by Odeny et al. found no significant differences in adverse event rates between HIV-positive and HIV-negative participants. These findings argue against using arbitrary CD4+ count thresholds to deny immunotherapy access.
CD4:CD8 ratio may be a more informative predictor. The CATCH-IT study found that HIV-positive patients with a CD4:CD8 ratio greater than 0.4 had a higher incidence of irAEs, possibly because a larger pool of circulating CD4+ T cells interacting with CD8+ T cells drives immune-related toxicities. This aligns with broader evidence that activated CD4+ memory T cells and T cell receptor diversity drive irAE pathogenesis following checkpoint blockade.
Specific risk factors for severe irAEs have been identified. Current evidence indicates that multiple factors significantly associate with severe irAEs in HIV-positive patients receiving ICIs: low baseline CD4+ T cell counts, prolonged AIDS duration, prior cancer-related surgery, and positive cytomegalovirus serology at ICI initiation. One trial also reported a fatal progression of KSHV-associated lymphoproliferation in a patient with pre-existing KSHV infection treated with pembrolizumab, highlighting the importance of pre-treatment comorbidity screening.
PD-L1 expression predicts response but with HIV-specific complexity. While high PD-L1 tumor expression generally predicts greater therapeutic sensitivity to checkpoint blockade, patients with low PD-L1 expression may still benefit, particularly when immunotherapy is combined with chemotherapy. Notably, higher PD-L1 expression correlates with poorer prognosis specifically in HIV-positive NSCLC patients but not in HIV-negative cases, suggesting that elevated PD-L1 in HIV-associated tumors may reflect greater immunosuppression rather than simply greater immunogenicity.
Tumor mutational burden and oncogenic drivers shape efficacy. High tumor mutational burden (TMB) generates more neoantigens and enhances T-cell recognition, correlating with better outcomes from checkpoint blockade. DNA mismatch repair deficiency (dMMR) leading to high microsatellite instability (MSI-H) serves as a robust predictive biomarker. In contrast, EGFR mutations and ALK fusions typically predict poor response to PD-1/PD-L1 monotherapy, while KRAS plus TP53 co-mutations are often associated with increased PD-L1 expression and higher tumor-infiltrating lymphocyte density.
The tumor microenvironment context matters significantly. An immune-inflamed tumor microenvironment characterized by abundant tumor-infiltrating lymphocytes and elevated inflammatory cytokines typically shows upregulated PD-1/PD-L1 signaling and is associated with improved clinical responses. HIV-positive NSCLC tissues showed greater immune cell infiltration compared to HIV-negative tissues, which may contribute to the therapeutic rationale for using checkpoint inhibitors in this population.
Gut microbiota influences immunotherapy efficacy. Growing evidence highlights the considerable influence of gut microbiota on checkpoint inhibitor outcomes. A balanced gut microbiome helps maintain a favorable systemic immune state and can potentiate immunotherapy efficacy, while dysbiosis or broad-spectrum antibiotic use may diminish treatment response. This factor deserves consideration in HIV-positive patients, who may have altered gut microbiomes due to HIV infection, prior opportunistic infections, and long-term ART use.
Current evidence supports PD-1/PD-L1 blockade for selected HIV-positive patients. The available evidence supports PD-1/PD-L1 inhibitors as a promising therapeutic option for HIV-positive patients with advanced lung cancer, particularly those maintaining ART-controlled viral loads and CD4+ T cell counts above 200 cells/mL. The dual mechanism of simultaneously activating anti-tumor immunity and potentially reversing HIV latency offers a novel clinical rationale that goes beyond cancer treatment alone.
Transient viral reservoir activation warrants vigilance during early treatment. Evidence suggests PD-1 inhibitor infusion may transiently reactivate the HIV reservoir, particularly in the first 24-48 hours following treatment initiation. This necessitates optimized therapeutic timing through multidisciplinary coordination between oncologists and infectious disease specialists, with close monitoring of viral load and inflammatory markers during early treatment cycles.
Major evidence gaps require prospective multicenter trials. Current limitations include very small sample sizes (median n=7 across clinical studies), predominantly retrospective study designs, imbalanced histological representation (most data from adenocarcinoma with very limited squamous cell carcinoma and SCLC data), unclear pharmacokinetic interactions between ICIs and antiretroviral drugs, and geographic underrepresentation of high HIV-burden regions in Africa, the Americas, and Southeast Asia.
Future research should integrate genomics with HIV reservoir monitoring. Future investigations should integrate tumor genomic profiling (TMB, TILs, MSI status) with systematic HIV reservoir monitoring to advance personalized immunotherapy strategies for this population. Evaluating the long-term consequences of PD-1 blockade on viral reservoir burden, immune reconstitution, and the potential for functional HIV cure represents an exciting frontier beyond cancer treatment.